Eli Lilly and Company (NYSE:LLY) Stock Price Down 2.6% – Here’s Why

Eli Lilly and Company (NYSE:LLY) fell 2.6% during mid-day trading on Wednesday . The company traded as low as $850.51 and last traded at $851.6470. 3,873,563 shares were traded during mid-day trading, an increase of 24% from the average session volume of 3,118,420 shares. The stock had previously closed at $874.00.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly struck a large AI‑driven gene‑editing partnership with Profluent worth up to $2.25B, giving exclusive rights to Profluent‑designed recombinase medicines and signaling deeper tech-enabled pipeline expansion that supports long‑term growth expectations. Eli Lilly Signs Up To $2.25 Billion AI Gene Editing Deal
• Positive Sentiment: Lilly agreed to buy Ajax Therapeutics for up to $2.3B to add a JAK2 inhibitor for myelofibrosis, reinforcing oncology pipeline diversification and providing near‑term M&A rationale for revenue optionality. Lilly Agrees To Buy Ajax Therapeutics For Up To $2.3 Billion
• Positive Sentiment: Guggenheim raised its price target on LLY and analysts remain broadly bullish (majority Buy ratings), which supports upside narrative and investor confidence in Lilly’s growth profile. Guggenheim Raises PT on Eli Lilly (LLY) Amid Several Acquisition Deals
• Neutral Sentiment: Earnings act as an imminent catalyst — previews expect strong revenue growth (high‑teens to mid‑30s percent on different metrics) but traders also price in notable post‑earnings moves, so results and commentary on product launches will drive short‑term volatility. Eli Lilly Stock Could Rise Sharply After Earnings
• Neutral Sentiment: Investors are seeking insight into Foundayo’s launch in upcoming reports — early metrics are limited, so the company can’t yet quantify uptake in quarterly financials, making guidance/comments the primary information source. Eli Lilly investors are eager for Foundayo insight after early launch data
• Negative Sentiment: Competitive pressure: Canada approved cheaper generic obesity drugs and early prescription counts for Lilly’s oral pill Foundayo are weak versus rivals, which raises near‑term market‑share concerns for the high‑margin obesity franchise. Eli Lilly Stock (LLY) Falls as Canada Approves Generic Weight-Loss Drugs
• Negative Sentiment: Market sentiment is also pressured by heavy insider selling and mixed institutional flows noted in discussion forums and data aggregators, which can amplify downside on an earnings miss or softer launch commentary. Eli Lilly Stock (LLY) Opinions on Foundayo Pill Launch

Analysts Set New Price Targets

A number of research firms have recently issued reports on LLY. Daiwa Securities Group lifted their price objective on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Weiss Ratings reiterated a “buy (b)” rating on shares of Eli Lilly and Company in a report on Friday, March 27th. Leerink Partners lowered their price objective on shares of Eli Lilly and Company from $1,296.00 to $1,058.00 and set an “outperform” rating on the stock in a report on Monday. Wall Street Zen downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Monday, April 6th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $1,216.52.

Eli Lilly and Company Stock Performance

The firm has a market capitalization of $804.65 billion, a price-to-earnings ratio of 37.11, a P/E/G ratio of 1.03 and a beta of 0.51. The stock’s fifty day moving average is $952.17 and its two-hundred day moving average is $986.25. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The business had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm’s revenue for the quarter was up 42.6% on a year-over-year basis. During the same period in the previous year, the company earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, analysts predict that Eli Lilly and Company will post 33.9 earnings per share for the current year.

Hedge Funds Weigh In On Eli Lilly and Company

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Maryland Capital Advisors Inc. bought a new position in Eli Lilly and Company during the fourth quarter worth $25,000. Osbon Capital Management LLC bought a new position in Eli Lilly and Company during the fourth quarter worth $25,000. Basso Capital Management L.P. bought a new position in Eli Lilly and Company during the fourth quarter worth $30,000. Miller Global Investments LLC bought a new position in Eli Lilly and Company during the fourth quarter worth $33,000. Finally, E Fund Management Hong Kong Co. Ltd. boosted its position in Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after purchasing an additional 24 shares during the period. 82.53% of the stock is owned by institutional investors.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.